CL2023001722A1 - Uso de composiciones vacunales que comprenden un dominio de unión al receptor del virus sars-cov-2 - Google Patents
Uso de composiciones vacunales que comprenden un dominio de unión al receptor del virus sars-cov-2Info
- Publication number
- CL2023001722A1 CL2023001722A1 CL2023001722A CL2023001722A CL2023001722A1 CL 2023001722 A1 CL2023001722 A1 CL 2023001722A1 CL 2023001722 A CL2023001722 A CL 2023001722A CL 2023001722 A CL2023001722 A CL 2023001722A CL 2023001722 A1 CL2023001722 A1 CL 2023001722A1
- Authority
- CL
- Chile
- Prior art keywords
- vaccine compositions
- binding domain
- receptor binding
- vaccine
- cov
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000005962 receptors Human genes 0.000 title abstract 3
- 108020003175 receptors Proteins 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 title 1
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 229960003983 diphtheria toxoid Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 229960001438 immunostimulant agent Drugs 0.000 abstract 1
- 239000003022 immunostimulating agent Substances 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 229940031626 subunit vaccine Drugs 0.000 abstract 1
- 229960000814 tetanus toxoid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se relaciona con el campo de la Biotecnología y la Medicina. Describe el uso de composiciones vacunales basadas en el dominio de unión al receptor del virus SARS-CoV-2 en el tratamiento de pacientes recuperados de COVID19 y en aquellos sujetos vacunados con plataformas vacunales diferentes a las vacunas de subunidades que no logran desarrollar una inmunidad protectora efectiva o cuando esta haya disminuido en el tiempo y no sea recomendable dar una dosis de refuerzo con la misma vacuna usada en la primoinmunización. En particular se describe dicho uso para las composiciones vacunales que comprenden un conjugado covalente entre el dominio de unión al receptor (RBD) y una proteína portadora como el toxoide tetánico, el toxoide diftérico y CRM197, las composiciones vacunales que tienen como antígeno el RBD ya sea con o sin el inmunoestimulante de vesículas derivadas de la membrana externa de Neisseria meningitidis grupo B.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20200101 | 2020-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001722A1 true CL2023001722A1 (es) | 2024-01-26 |
Family
ID=80445721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001722A CL2023001722A1 (es) | 2020-12-16 | 2023-06-14 | Uso de composiciones vacunales que comprenden un dominio de unión al receptor del virus sars-cov-2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240042013A1 (es) |
| EP (1) | EP4265272A1 (es) |
| JP (1) | JP2024510065A (es) |
| KR (1) | KR20240035738A (es) |
| CN (1) | CN117440825A (es) |
| AU (1) | AU2021404744A1 (es) |
| CA (1) | CA3202603A1 (es) |
| CL (1) | CL2023001722A1 (es) |
| WO (1) | WO2022127946A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022012527A (es) * | 2020-04-06 | 2023-03-13 | Eisai R&D Man Co Ltd | Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria. |
| BR112022020486A2 (pt) * | 2020-04-10 | 2023-01-17 | Akston Biosciences Corp | Imunoterapia específica de antígeno para proteínas de fusão de covid-19 e métodos de uso |
| EP4181953A2 (en) * | 2020-07-14 | 2023-05-24 | RiboxX GmbH | Post-exposure vaccination against viral respiratory infections |
-
2021
- 2021-12-14 EP EP21854867.5A patent/EP4265272A1/en active Pending
- 2021-12-14 CA CA3202603A patent/CA3202603A1/en active Pending
- 2021-12-14 AU AU2021404744A patent/AU2021404744A1/en active Pending
- 2021-12-14 WO PCT/CU2021/050014 patent/WO2022127946A1/es active Application Filing
- 2021-12-14 KR KR1020237024030A patent/KR20240035738A/ko unknown
- 2021-12-14 JP JP2023536891A patent/JP2024510065A/ja active Pending
- 2021-12-14 US US18/266,486 patent/US20240042013A1/en active Pending
- 2021-12-14 CN CN202180093131.7A patent/CN117440825A/zh active Pending
-
2023
- 2023-06-14 CL CL2023001722A patent/CL2023001722A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021404744A1 (en) | 2023-07-06 |
| WO2022127946A1 (es) | 2022-06-23 |
| CA3202603A1 (en) | 2022-06-23 |
| EP4265272A1 (en) | 2023-10-25 |
| JP2024510065A (ja) | 2024-03-06 |
| CN117440825A (zh) | 2024-01-23 |
| US20240042013A1 (en) | 2024-02-08 |
| KR20240035738A (ko) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leroux-Roels | Unmet needs in modern vaccinology: adjuvants to improve the immune response | |
| TW200722101A (en) | Novel composition | |
| Kim et al. | Improved influenza vaccination in the skin using vaccine coated microneedles | |
| NI202000040A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos | |
| Vogel et al. | Emulsion-based adjuvants for influenza vaccines | |
| Herzog | Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature | |
| DOP2021000127A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso | |
| Vono et al. | Overcoming the neonatal limitations of inducing germinal centers through liposome-based adjuvants including C-type lectin agonists trehalose dibehenate or curdlan | |
| MX2009000660A (es) | Vacuna de influenza. | |
| RU2009126604A (ru) | Вакцина против salmonella | |
| Levine et al. | Vaccines and vaccination in historical perspective | |
| Qayoom et al. | Adverse cutaneous drug reactions-a clinico-demographic study in a tertiary care teaching hospital of the Kashmir Valley, India | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| Stinson et al. | Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles | |
| CO2022012272A2 (es) | Vacunas contra el coronavirus y métodos de uso | |
| BRPI0606165A2 (pt) | método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada | |
| Cao et al. | An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice | |
| CL2023001722A1 (es) | Uso de composiciones vacunales que comprenden un dominio de unión al receptor del virus sars-cov-2 | |
| DK3076997T3 (en) | SVINEVACCINE v PRRS AND LAWSONIA INTRACELLULARIS | |
| Depelsenaire et al. | Introduction to vaccines and vaccination | |
| Yang et al. | Anti-caries vaccine based on clinical cold-adapted influenza vaccine: A promising alternative for scientific and public-health protection against dental caries | |
| JP2019520090A (ja) | 弱毒変異型ジカウイルスを含むワクチン組成物 | |
| Silveira et al. | Quillaja brasiliensis nanoparticle adjuvant formulation improves the efficacy of an inactivated trivalent influenza vaccine in mice | |
| EA202190914A1 (ru) | Иммуногенные композиции | |
| US20150209422A1 (en) | Immunization with rabies virus vector expressing foreign protein antigen |